Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/29525
Type
ArticleCopyright
Restricted access
Embargo date
2030-01-01
Collections
- IOC - Artigos de Periódicos [12642]
Metadata
Show full item record
EFFICACY OF APIGENIN AND MILTEFOSINE COMBINATION THERAPY AGAINST EXPERIMENTAL CUTANEOUS LEISHMANIASIS
terapia combinada
Apigenina
Miltefosina
Eficácia
Affilliation
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Bioquímica de Tripanossomatideos. Rio de Janeiro, RJ. Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Bioquímica de Tripanossomatideos. Rio de Janeiro, RJ. Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Bioquímica de Tripanossomatideos. Rio de Janeiro, RJ. Brasil.
Abstract
Leishmaniasis is a neglected tropical disease caused by several different species of Leishmania. Treatment of leishmaniasis involves a limited drug arsenal that is associated with severe side effects, high costs, and drug resistance. Therefore, combination therapy has emerged as a strategy to improve leishmaniasis treatment. Here, we report the interaction of miltefosine and apigenin in vitro and in vivo. Combination therapy using low doses of these two drugs results in good clinical and parasitological responses.
Keywords in Portuguese
Leishmaniose Tegumentar Experimentalterapia combinada
Apigenina
Miltefosina
Eficácia
Share